No Prescription |
 |
 | ||
|
Canesten Vag Cream 6day Generic Clotrimazole |
|
| ||
No Prescription » Prescription Drugs 3 » Canesten Vag Cream 6day Generic Clotrimazole Canesten Clotrimazole 6 Day cream are indicated for the topical treatment of vulvovaginal candidiasis. Canesten Clotrimazole cream may also be used in conjunction with Canesten Clotrimazole vaginal pessaries in the management of Candida vulvovaginitis or infection of the peri-anal area while application of the cream to the glans penis of the partner may help prevent re-infection of the female. Buy Canesten Vag Cream 6day Generic Clotrimazole and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About Canesten Vag Cream 6day Generic Clotrimazole: Product Type: Prescription Drugs 3 Canesten Vag Cream 6day ( Generic Clotrimazole ) Canesten Vag Cream 6day (Generic Clotrimazole) Generic Clotrimazole 1%w/w 105gm(3 x 35gm) 35gm Generic Clotrimazole Canesten Vag Cream 6day
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
